Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 2:34 AM
Ignite Modification Date: 2025-12-25 @ 2:34 AM
NCT ID: NCT07087834
Eligibility Criteria: In Turkey, the National Cancer Screening Program for men involves a fecal occult blood test every two years for those aged 50-70 and a colonoscopy every 10 years. Although men under the age of 50 are not included in the routine screening program, there are many simple screening methods for various cancers. After reviewing the literature and considering the current prevalence of cancer, it was decided that men aged 18 and older are suitable for sampling. The inclusion criteria for the study were determined in accordance with the relevant literature (Abasi et al., 2021; Echeverri et al., 2022; Makarov et al., 2021; Vernon et al., 2024). Inclusion criteria To be included in the study, participants must meet all of the following criteria: * Be 30 years of age or older at the time of the study, * Be at least literate, * Have no cognitive, visual, or orthopedic impairments that would prevent them from completing the questionnaires, * Be able to speak and understand Turkish, * Have no previous history of cancer diagnosis or cancer treatment, * Agree to participate in the study. Exclusion criteria Participants are excluded from the study if they meet any of the following criteria: * Having previously had cancer and undergone cancer treatment, * Not currently employed at the institution (e.g., on temporary assignment), * Refusing to participate in the study.
Healthy Volunteers: True
Sex: MALE
Minimum Age: 30 Years
Study: NCT07087834
Study Brief:
Protocol Section: NCT07087834